Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price objective on Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating on the stock in a report on Thursday, May 2nd.

Minerva Neurosciences Price Performance

Shares of NASDAQ NERV opened at $3.19 on Thursday. The company has a market cap of $22.30 million, a PE ratio of -0.71 and a beta of 0.13. The company has a 50-day simple moving average of $2.78 and a 200-day simple moving average of $4.63. Minerva Neurosciences has a 12 month low of $2.26 and a 12 month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. On average, analysts anticipate that Minerva Neurosciences will post -1.89 EPS for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.